Health Care·Pharmaceuticals·$4.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.68 | N/A | -20.35% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.68 | N/A | -20.35% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the difficulties faced during the quarter. They emphasized the importance of innovation and product pipeline but did not provide specific guidance.
Management expressed concerns about ongoing challenges in the market.
They highlighted the need for continued focus on product development.
No specific guidance was provided for future quarters.
Crinetics Pharmaceuticals reported a wider-than-expected loss per share, which contributed to the stock's decline of 3.41% following the earnings announcement. The lack of revenue figures and guidance may raise concerns among investors about the company's near-term prospects. Management's cautious tone suggests that challenges remain, which could impact future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
TANGO THERAPEUTICS I
Mar 28, 2022